Prevention of shedding and re-shedding of Toxoplasma gondii oocysts in experimentally infected cats treated with oral Clindamycin: a preliminary study.
This work aimed to evaluate the effects of preventive oral Clindamycin in cats infected with Toxoplasma gondii. Twelve short hair cats were divided into two groups (group 1 and group 2). No titres of T. gondii antibodies were detected in these cats before the experiment. The animals from group 1 were infected with tissue cysts of T. gondii and group 2 were infected and treated with Clindamycin (20 mg/kg/day). The infection was done with almost 40-50 tissue cysts for each cat on day 0. The cats from group 2 were treated with Clindamycin by oral rout for 24 days (from day -3 to day 21). At day 45, the groups 1 and 2 were divided into two subgroups with three animals each. Subgroups 1A and 2A were immunosuppressed with dexamethasone (1 mg/kg/day) for30 days and subgroups 1B and 2B were not immunosuppressed. Faecal exam looking for oocyst shedding was made by 30 days after T. gondii infection, and for 30 days after immunosuppression. All kittens from group 1 shedding oocysts after infection, while animals from group 2 did not shed. After immunosuppression period, all animals from group 1A re-shed oocysts and animals from group 2A remained without shed. However, 2 (66.6%) of the kittens from subgroup 2B shed oocysts 19-20 days after re-challenge. Based on this preliminary study, Clindamycin had a complete inhibitory effect on shedding of oocysts by cats, even under severe immunosuppression, which is a new finding not reported elsewhere.
Malmasi
A
A
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. malmasia@vetmed.ut.ac.ir
Mosallanejad
B
B
Mohebali
M
M
Sharifian Fard
M
M
Taheri
M
M
D000284:Administration, Oral; D000818:Animals; D002371:Cat Diseases / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control* / Q000635:transmission; D002415:Cats; D002981:Clindamycin / Q000494:pharmacology*; D003049:Coccidiostats / Q000494:pharmacology; D005243:Feces / Q000469:parasitology*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D011634:Public Health; D014122:Toxoplasma / Q000276:immunology / Q000302:isolation & purification* / Q000502:physiology; D014124:Toxoplasmosis, Animal / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control* / Q000635:transmission; D015047:Zoonoses
D003049:Coccidiostats; D002981:Clindamycin